Case files of the medical toxicology fellowship at Banner good samaritan medical center in Phoenix, AZ: A non-warfarin anticoagulant overdose

Journal of Medical Toxicology

Volumn 5, Issue 4, 2009, Pages 242-249

  Gresham, Chip ^a   Levine, Michael ^a   Ruha, Anne Michelle ^a  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

Author keywords

Adp antagonists; Factor Xa inhibitors; Low molecular weight heparins; Overdose

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DESMOPRESSIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; SALICYLIC ACID DERIVATIVE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; XIMELAGATRAN; BLOOD CLOTTING FACTOR 5;

APLASTIC ANEMIA; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD TRANSFUSION; CASE STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ELECTRONIC MEDICAL RECORD; EMERGENCY WARD; GENE MUTATION; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MEDICAL EDUCATION; MUNCHAUSEN SYNDROME; NEUTROPENIA; NONHUMAN; OUTPATIENT CARE; PATIENT CARE; PATIENT MONITORING; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SUICIDE ATTEMPT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; CASE REPORT; GENETICS; INTOXICATION; MALE; MEDICAL RECORD; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ANTICOAGULANTS; ARIZONA; ENOXAPARIN; FACTOR V; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUNCHAUSEN SYNDROME; OVERDOSE; SUICIDE, ATTEMPTED; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM;

EID: 75349093047     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/BF03178275     Document Type: Article

References (56)

1. Fields JM, Goyal M. Venothromboembolism. Emerg Med Clin North Am. 2008;26:649-683.
2. McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother. 2002;36:1042-1057.
3. Jacobson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol. 2004;17:55-64.
4. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline. Am J Cardiovasc Drugs. 2007;7:423-432.
5. Lubbe DF, Berger PB. The thienopyridines. J Interven Cardiol. 2002;15:85-94.
6. Plosker GL, Lyseng-Williamson KA. Clopidogrel: A review of its use in the prevention of thrombosis. Drugs. 2007;67:613-646.
7. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667-1672.
8. Ticlid [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2001.
9. Abuzahra M, Pillai M, Caldera A, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Am J Cardiol. 2008;102:401-403.
10. Thebault JJ, Kieffer G, Cariou R. Single dose pharmaco-dynamics of clopidogrel. Semin Thromb Hemost. 1999;25 (Suppl 2):3-8.
11. Riley AB, Tafreshi MJ, Haber SL. Prasugrel: a novel antiplatelet agent. Am J Health-Syst Pharm. 2008;65:10019-10028.
12. Samama MM, Gerotziafas GT. Comparative pharmaco-kinetics of LMWHs. Semin Thromb Hemost. 2000;26(Suppl 1): 31-38.
13. George-Phillips KL, Bungard TJ. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Pharmacotherapy. 2006;26:1479-1490.
14. Menajovsky LB. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med. 2005; 118(Suppl 8A):21S-30S.
15. Cheng JW. Fondaparinux: A new antithrombotic agent. Clin Ther. 2002;24:1757-1769.
16. Keam SJ, Goa KL. Fondaparinux sodium. Drugs. 2002;62: 1673-1685.
17. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin. 2008;26:145-155.
18. Linkins LA, Weitz JI. New anticoagulant therapy. Annu Rev Med. 2005;56:63-77.
19. Bauer KA. New anticoagulants. Curr Opin Hematol. 2008;15: 509-515.
20. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105:453-463.
21. Agnelli G, Becattini C. New anticoagulants. Semin Thromb Hemost. 2006;32:793-802.
22. Turpie AG, Gallus AS, Hoek JA, et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-625.
23. Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmith Kline; October 2008.
24. Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med J Aust. 2009;190:379-383.
25. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65: 1520-1529.
26. Hirsh J. Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):188-203S.
27. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
28. Wiernikowski JT, Chan A, Lo G. Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin. Thromb Res. 2007;120:303-305.
29. Saw J, Kereiakes DJ, Mahaffey KW, et al. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res. 2003;112:301-306.
30. Robertson JD, Brandao L, Williams S, et al. Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children. Thromb Res. 2008;122:867-869.
31. Nieuwenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-2343.
32. Geiger J, Teichmann L, Grossman R, et al. Monitoring clopidogrel action: comparison of methods. Clin Chem. 2005;51: 957-965.
33. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the Verify Now-P2Y12 rapid analyzer: The VERify Thrombosis Risk Assessment (VERITAS) study. Thromb Res. 2007;119:277-284.
34. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987.
35. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2008.
36. Mani H, Toennes SW, Linnemann B, et al. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? Ther Drug Monit. 2008;30:84-89.
37. Lau WC, Gurbel PA, Watkins PB. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.
38. Bennett JS. Novel platelet inhibitors. Annu Rev Med. 2001;52:161-184.
39. Jonas S, Grieco G. An approach to estimation of the risk of TTP during clopidogrel therapy. Stroke. 2004;35:537-538.
40. Kocabay G, Okçular I, Akkaya V, et al. Suicide attempt with clopidogrel. Hum Exp Toxicol. 2006;25:731-734.
41. Chawla LS, Moore G, Seneff MG. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. Obes Surg. 2004;14:695-698.
42. Cherfan A, Arabi Y, Al Askar A, et al. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Pharmacotherapy. 2007;27:755-759.
43. Weinsheimer RL, Libby E, Howdieshell TR. Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin. Am Surg. 2005;71:132-134.
44. Kam PCA, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia. 2003;58: 28-35.
45. Levy JH, Tanaka KA. The anticoagulated patient: strategies for effective blood loss management. Surgery. 2007;142: S71-S77.
46. Greer IA, McLaren M, Belch JJ, et al. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia. Haemostasis. 1986;16:15-19.
47. Barnhart MI, Chen S, Lusher JM. DDAVP: does the drug have a direct effect on the vessel wall? Thromb Res. 1983; 31:239-253.
48. Leithauser B, Zielske D, Seyfert UT, et al. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39:293-302.
49. Herbert JM, Bernat A, Maffrand JP. Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res. 1993;71:433-441.
50. Bang CJ, Berstad A, Talstad I. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis. 1991;21:155-160.
51. Sugiyama T, Itoh M, Ohtawa M, et al. Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics. Thromb Res. 1992; 68:119-129.
52. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007;18:547-553.
53. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550-2554.
54. Abrams PJ, Emerson CR. Rivaroxaban: A novel, oral, direct factorXa inhibitor. Pharmacotherapy. 2009;29:167-181.
55. Bates SM, Weitz JI. New anticoagulants: beyond heparin, low molecular weight heparin, and warfarin. Br J Pharmacol. 2005;144:1017-1028.
56. Pradaxa [package insert]. Germany: Boehringer Ingelheim; 2008.